サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1513885

小児用医薬品とワクチンの世界市場

Pediatric Drugs and Vaccines

出版日
ページ情報
英文 292 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
小児用医薬品とワクチンの世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 292 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

小児用医薬品とワクチンの世界市場は2030年までに1,567億米ドルに達する見込み

2023年に1,047億米ドルと推定された小児用医薬品とワクチンの世界市場は、2030年には1,567億米ドルに達し、分析期間2023-2030年のCAGRは5.9%で成長すると予測されます。本レポートで分析したセグメントの1つであるコンジュゲート技術は、CAGR 7.1%を記録し、分析期間終了時には520億米ドルに達すると予想されます。ライブアッテネート技術分野の成長率は、分析期間中CAGR 6.1%と推定されます。

米国市場は282億米ドルと推定、中国はCAGR 9.9%で成長予測

米国の小児用医薬品とワクチン市場は2023年に282億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに354億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは9.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.0％と6.4％と予測されています。欧州では、ドイツがCAGR 3.3%で成長すると予測されています。

小児用医薬品とワクチン-主要動向と促進要因

小児用医薬品とワクチンは、乳幼児期から思春期までの子どもの健康と福祉に特化した、医薬品業界における重要なセグメントです。これらの医薬品や予防接種は、安全性、有効性、適切な投与量を確保しながら、幼い患者特有の生理的ニーズに対応するよう特別に処方されます。小児用医薬品は、感染症、慢性疾患、栄養欠乏症、急性疾患など、幅広い治療領域をカバーしています。ワクチンは、はしか、おたふくかぜ、風疹、ポリオなど、生命を脅かす可能性のある様々な病気に対する免疫を提供することで、同様に重要な役割を果たしています。小児用医薬品とワクチンの開発・承認プロセスには、患者集団の脆弱性を考慮し、厳格な安全基準を満たすための厳格な臨床試験と規制当局による精査が含まれます。

いくつかの動向と革新が小児用医薬品とワクチンの状況を形成しています。重要な動向の一つは、個々の患者の遺伝子構成に基づいて治療を調整し、治療成績を向上させ、副作用を最小限に抑える個別化医療が重視されるようになっていることです。バイオテクノロジーの進歩は、COVID-19パンデミックの際に注目されたmRNAワクチンのような、新しいワクチン・プラットフォームの開発につながっています。これらのプラットフォームは、迅速な開発と高い有効性が期待できます。さらに、1回の注射で複数の疾病を予防し、コンプライアンスと接種率を向上させる混合ワクチンへの注目も高まっています。モバイルヘルスアプリケーションや遠隔医療を含むデジタルヘルス技術の統合は、患者管理と治療レジメンへのアドヒアランスを強化しています。さらに、世界ヘルスイニシアチブやパートナーシップは、中低所得国における必須ワクチンや医薬品へのアクセス向上に役立っています。

小児用医薬品とワクチン市場の成長は、いくつかの要因によってもたらされます。ドラッグの製剤化とデリバリー・システムの技術的進歩により、チュアブル錠や溶解可能なストリップなど、より効果的で小児にやさしい医薬品の開発が可能になりつつあります。喘息、糖尿病、てんかんを含む小児の慢性疾患の罹患率が上昇しており、長期的な治療ソリューションに対する需要が高まっています。適時の予防接種と予防医療対策の重要性に対する保護者や介護者の意識の高まりが、予防接種率の上昇につながっています。さらに、小児ヘルスケアプログラムに対する政府の取り組みや資金援助が、市場の成長を大きく後押ししています。規制上の優遇措置に後押しされ、小児臨床試験の範囲が拡大していることも、新しく革新的な治療のイントロダクションを加速させています。最後に、ワクチン接種キャンペーンを通じて感染症の撲滅に世界的に注力していることが、小児用ワクチンの開発と流通を後押しし、世界中の子どもたちの健康状態の改善を確実なものにしています。

調査対象企業の例（注目の76社）

  • Abbott Laboratories
  • Allergan Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc.
  • GlaxoSmithKline Plc
  • Janssen Biologics B.V
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi
  • Shionogi Inc.
  • Shire Pharmaceuticals Group Plc

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6503

Global Pediatric Drugs and Vaccines Market to Reach US$156.7 Billion by 2030

The global market for Pediatric Drugs and Vaccines estimated at US$104.7 Billion in the year 2023, is expected to reach US$156.7 Billion by 2030, growing at a CAGR of 5.9% over the analysis period 2023-2030. Conjugate Technology, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$52.0 Billion by the end of the analysis period. Growth in the Live Attenuated Technology segment is estimated at 6.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$28.2 Billion While China is Forecast to Grow at 9.9% CAGR

The Pediatric Drugs and Vaccines market in the U.S. is estimated at US$28.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$35.4 Billion by the year 2030 trailing a CAGR of 9.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 6.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Pediatric Drugs and Vaccines - Key Trends and Drivers

Pediatric drugs and vaccines represent a crucial segment in the pharmaceutical industry, dedicated to the health and wellbeing of children from infancy through adolescence. These medications and immunizations are specifically formulated to address the unique physiological needs of young patients, ensuring safety, efficacy, and appropriate dosing. Pediatric drugs cover a broad spectrum of therapeutic areas, including infectious diseases, chronic illnesses, nutritional deficiencies, and acute conditions. Vaccines play an equally vital role by providing immunity against a range of potentially life-threatening diseases such as measles, mumps, rubella, polio, and more. The development and approval process for pediatric drugs and vaccines involve rigorous clinical trials and regulatory scrutiny to ensure they meet stringent safety standards, given the vulnerable nature of the patient population.

Several trends and innovations are shaping the landscape of pediatric drugs and vaccines. One significant trend is the increasing emphasis on personalized medicine, which tailors treatments based on the genetic makeup of individual patients, thus improving therapeutic outcomes and minimizing adverse effects. Advances in biotechnology are leading to the development of novel vaccine platforms, such as mRNA vaccines, which have gained prominence during the COVID-19 pandemic. These platforms offer the potential for rapid development and high efficacy. Additionally, there is a growing focus on combination vaccines, which protect against multiple diseases with a single injection, thereby improving compliance and coverage rates. The integration of digital health technologies, including mobile health applications and telemedicine, is enhancing patient management and adherence to treatment regimens. Moreover, global health initiatives and partnerships are instrumental in increasing access to essential vaccines and medications in low- and middle-income countries.

The growth in the pediatric drugs and vaccines market is driven by several factors. Technological advancements in drug formulation and delivery systems are enabling the development of more effective and child-friendly medications, such as chewable tablets and dissolvable strips. The rising incidence of chronic diseases in children, including asthma, diabetes, and epilepsy, is fueling demand for long-term therapeutic solutions. Increasing awareness among parents and caregivers about the importance of timely vaccinations and preventive healthcare measures is leading to higher immunization rates. Additionally, government initiatives and funding for pediatric healthcare programs are providing a significant boost to market growth. The expanding scope of pediatric clinical trials, driven by regulatory incentives, is accelerating the introduction of new and innovative treatments. Lastly, the global focus on eradicating infectious diseases through vaccination campaigns is propelling the development and distribution of pediatric vaccines, ensuring better health outcomes for children worldwide.

Select Competitors (Total 76 Featured) -

  • Abbott Laboratories
  • Allergan Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc.
  • GlaxoSmithKline Plc
  • Janssen Biologics B.V
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi
  • Shionogi Inc.
  • Shire Pharmaceuticals Group Plc

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Pediatric Drugs and Vaccines - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Incidence of Chronic Pediatric Diseases Throws the Spotlight on Long-Term Therapeutic Solutions
    • Advancements in Drug Formulation Propel Growth in Pediatric Medications Market
    • Rising Awareness about Preventive Healthcare Expands Addressable Market Opportunity for Pediatric Vaccines
    • Innovations in Vaccine Platforms Strengthen Business Case for Next-Generation Immunizations
    • Government Initiatives and Funding Generates Demand for Pediatric Healthcare Programs
    • Integration of Digital Health Technologies Drives Adoption of Advanced Patient Management Tools
    • Combination Vaccines Accelerate Demand by Improving Compliance and Coverage Rates
    • Global Health Initiatives Ensure Increasing Access to Essential Pediatric Vaccines
    • Personalized Medicine Enhances Therapeutic Outcomes for Pediatric Patients
    • Advances in Drug Delivery Systems Sustain Growth in Pediatric Drug Administration
    • Expansion of Telemedicine Services Drives Adoption of Remote Pediatric Care Solutions
    • Rising Investment in Biotechnology Generates Opportunities for Novel Pediatric Treatments
    • Increasing Focus on Eradicating Infectious Diseases Propels Growth in Pediatric Vaccination Programs
    • Enhanced Safety and Efficacy Standards Generate Confidence in Pediatric Drug and Vaccine Adoption
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Pediatric Drugs and Vaccines Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Pediatric Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Conjugate by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Conjugate by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Live Attenuated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Live Attenuated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Inactivated by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Inactivated by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Subunit by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Subunit by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Toxoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Toxoid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Toxoid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: World 16-Year Perspective for Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • JAPAN
    • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • CHINA
    • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • EUROPE
    • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • FRANCE
    • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • GERMANY
    • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • INDIA
    • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030
  • AFRICA
    • Pediatric Drugs and Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Pediatric Drugs and Vaccines by Technology - Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Pediatric Drugs and Vaccines by Technology - Percentage Breakdown of Value Sales for Conjugate, Live Attenuated, Inactivated, Subunit, Toxoid and Other Technologies for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Pediatric Drugs and Vaccines by Product Type - Vaccines and Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Pediatric Drugs and Vaccines by Product Type - Percentage Breakdown of Value Sales for Vaccines and Drugs for the Years 2014, 2024 & 2030

IV. COMPETITION